SHR-1179
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 18, 2026
A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study of SHR-1179 Injection in Participants With Obesity
(clinicaltrials.gov)
- P1 | N=50 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
New P1 trial • Genetic Disorders • Obesity
1 to 1
Of
1
Go to page
1